• Publications
  • Influence
Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population
Background. The Surveillance, Epidemiology and End Results (SEER)-Medicare–linked database combines clinical information from population-based cancer registries with claims information from theExpand
  • 1,496
  • 91
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.
BACKGROUND The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central CancerExpand
  • 1,027
  • 44
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
PURPOSE To address whether all medically fit patients with curatively resected stage II colon cancer should be offered adjuvant chemotherapy as part of routine clinical practice, to identify patientsExpand
  • 1,125
  • 41
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
PURPOSE To establish evidence of activity, or lack thereof, of cetuximab-based therapy in patients with refractory colorectal cancer with tumors that do not demonstrate epidermal growth factorExpand
  • 1,078
  • 28
How to build and interpret a nomogram for cancer prognosis.
Nomograms are widely used for cancer prognosis, primarily because of their ability to reduce statistical predictive models into a single numerical estimate of the probability of an event, such asExpand
  • 725
  • 24
Patients' expectations about effects of chemotherapy for advanced cancer.
BACKGROUND Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative. METHODS We studied 1193 patientsExpand
  • 513
  • 21
  • Open Access
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
PURPOSE The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer.Expand
  • 655
  • 21
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.
PURPOSE To review the evidence about the efficacy and utility of radiofrequency ablation (RFA) for hepatic metastases from colorectal cancer (CRHM). METHODS The American Society of ClinicalExpand
  • 358
  • 19
Primary care physicians who treat blacks and whites.
BACKGROUND In the United States, black patients generally receive lower-quality health care than white patients. Black patients may receive their care from a subgroup of physicians whoseExpand
  • 606
  • 18
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.
PURPOSE There is growing interest to enhance symptom monitoring during routine cancer care using patient-reported outcomes, but evidence of impact on clinical outcomes is limited. METHODS WeExpand
  • 657
  • 18
  • Open Access